Race Oncology Advances RC220 Trial and Appoints New Medical Leaders

Race Oncology has reported progress in its RC220 trial, successfully treating its first patient with the reformulated bisantrene in combination with doxorubicin for advanced solid tumors. The company has also appointed new medical leaders, including Dr. Jose Iglesias as CMO and Dr. Simon Fisher as VP of medical. Race's financial position remains strong, with a cash position of $13.67 million as of June 30, 2025.

Race Oncology Ltd (ASX: RAC, OTC: RAONF) has made significant strides in its RC220 trial, marking a critical milestone with the successful treatment of its first patient using the reformulated bisantrene in combination with doxorubicin for advanced solid tumours. The company's Phase 1 trial, aimed at delivering enhanced anticancer efficacy while minimizing cardiotoxicity, has shown promising results [1].

The trial's success was achieved without any adverse events, including phlebitis, in patients with advanced solid tumours. This sets the stage for further clinical testing to assess RC220's potential to offer cardioprotection [1].

In addition to its clinical progress, Race Oncology has bolstered its leadership team by appointing Dr Jose Iglesias as chief medical officer and Dr Simon Fisher as vice president of medical. These appointments signal the company's commitment to expanding its expertise and advancing the development of RC220 to address high unmet needs in cancer care [1].

The company's financial position remains robust, with a cash position of $13.67 million as of June 30, 2025. More than 83% of the quarter's expenditure was directed towards research and development (R&D) and drug manufacturing, underscoring Race's focus on advancing its clinical pipeline. The company is well-positioned to fund its operations through to the end of 2026, allowing it to progress both the RC220 trial and ongoing drug development initiatives [1].

Race Oncology has also made strategic developments in its clinical trial, including key site activations for the Phase 1 trial of RC220 in combination with doxorubicin. Patient enrolment is now underway at multiple sites, bringing the company closer to demonstrating RC220's efficacy and safety profile in a larger cohort of patients [1].

In post-quarter news, Race received ethics approval to begin the Phase 1 trial of RC220 at two hospitals in Hong Kong, marking an important expansion of its clinical footprint. Additionally, CEO Dr Daniel Tillett has been invited to present at the prestigious European Society of Medical Oncology (ESMO) 2025 conference, which will help raise the company's profile in the global oncology community [1].

References:
[1] https://www.proactiveinvestors.com/companies/news/1075233/race-oncology-reports-strong-progress-in-rc220-trial-and-appoints-new-medical-leaders-1075233.html